SANES

9.27

+0.25%↑

BBVA

18.735

+0.78%↑

ALV

369.3

-0.59%↓

MUV2

540.2

-0.63%↓

INGA

22.485

+0.63%↑

SANES

9.27

+0.25%↑

BBVA

18.735

+0.78%↑

ALV

369.3

-0.59%↓

MUV2

540.2

-0.63%↓

INGA

22.485

+0.63%↑

SANES

9.27

+0.25%↑

BBVA

18.735

+0.78%↑

ALV

369.3

-0.59%↓

MUV2

540.2

-0.63%↓

INGA

22.485

+0.63%↑

SANES

9.27

+0.25%↑

BBVA

18.735

+0.78%↑

ALV

369.3

-0.59%↓

MUV2

540.2

-0.63%↓

INGA

22.485

+0.63%↑

SANES

9.27

+0.25%↑

BBVA

18.735

+0.78%↑

ALV

369.3

-0.59%↓

MUV2

540.2

-0.63%↓

INGA

22.485

+0.63%↑

Search

Bayer AG

Closed

SectorFinance

30.405 -0.34

Overview

Share price change

24h

Current

Min

30.155

Max

30.63

Key metrics

By Trading Economics

Income

-773M

-963M

Sales

-1.1B

9.7B

EPS

1.23

Dividend yield

0.4

Profit margin

-9.969

Employees

88,502

EBITDA

-3.4B

236M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

-4.17% downside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.40%

3.95%

Market Stats

By TradingEconomics

Market Cap

3.6B

30B

Previous open

30.75

Previous close

30.405

News Sentiment

By Acuity

26%

74%

72 / 528 Finance

Technical Score

By Trading Central

Confidence

Bearish Evidence

Bayer AG Chart

Past performance is not a reliable indicator of future results.

Related News

24 Nov 2025, 11:12 UTC

Major Market Movers

Bayer Shares Jump After Drug Candidate Shows Stroke Prevention Potential -- Update

12 Nov 2025, 07:32 UTC

Earnings

Bayer Posts Net Loss on Litigation Hit

6 Aug 2025, 06:18 UTC

Earnings

Bayer Loss Widens on Litigation Charges

24 Nov 2025, 09:50 UTC

Hot Stocks
Acquisitions, Mergers, Takeovers

Stocks to Watch Monday: Alibaba, Tesla, Alphabet, Bayer -- WSJ

12 Nov 2025, 11:15 UTC

Market Talk
Earnings

Bayer's Crop Science Unit Drives Strong Results -- Market Talk

12 Nov 2025, 06:33 UTC

Earnings

Bayer Affirms Objective to Significantly Contain Litigation Risk by End of 2026

12 Nov 2025, 06:31 UTC

Earnings

Analysts Had Seen Bayer 3Q Net Loss at EUR413M

12 Nov 2025, 06:31 UTC

Earnings

Bayer 3Q Net Loss EUR963M

12 Nov 2025, 06:30 UTC

Earnings

Analysts Had Seen Bayer 3Q EBITDA Before Special Items at EUR1.27B

12 Nov 2025, 06:30 UTC

Earnings

Bayer 3Q EBITDA Before Special Items EUR1.51B

12 Nov 2025, 06:30 UTC

Earnings

Analysts Had Seen Bayer 3Q Sales at EUR9.69B

12 Nov 2025, 06:30 UTC

Earnings

Bayer 3Q Sales EUR9.66B

12 Nov 2025, 06:30 UTC

Earnings

Bayer Backs 2025 View

6 Aug 2025, 15:01 UTC

Market Talk
Earnings

Bayer Expects Bumper U.S. Crop -- Market Talk

6 Aug 2025, 14:52 UTC

Market Talk

Bayer says Litigation Situation With Roundup 'Unsustainable' -- Market Talk

6 Aug 2025, 09:05 UTC

Market Talk

Bayer Expects Weedkiller Dicamba Back on U.S. Market in 2026 -- Market Talk

6 Aug 2025, 07:27 UTC

Market Talk
Earnings

Bayer's Results Deliver Few Surprises -- Market Talk

6 Aug 2025, 05:43 UTC

Earnings

Bayer: Crop Science Division Now in a Position to Streamline Production and Operations

6 Aug 2025, 05:43 UTC

Earnings

Bayer: Making Headway on Plan to Improve Profitability in Agricultural Business

6 Aug 2025, 05:42 UTC

Earnings

Bayer Affirms Objective to Significantly Contain Litigation Risk by End of 2026

6 Aug 2025, 05:41 UTC

Earnings

Bayer Expects Significant Currency Fluctuations With Headwinds on Sales and Profits, Favorable Effects on Debt

6 Aug 2025, 05:41 UTC

Earnings

Bayer: 2H Will Be Marked by Progress on Strategic Priorities, Launches, Geopolitical and Currency Crosswinds

6 Aug 2025, 05:33 UTC

Earnings

Bayer 2Q Net Loss EUR199M

6 Aug 2025, 05:32 UTC

Earnings

Bayer Had Pre-Announced 2Q Ebitda Before Special Items at EUR2.1B

6 Aug 2025, 05:32 UTC

Earnings

Bayer 2Q Ebitda Before Special Items EUR2.11B

6 Aug 2025, 05:32 UTC

Earnings

Bayer Had Pre-Announced 2Q Sales at EUR10.7B

6 Aug 2025, 05:32 UTC

Earnings

Bayer 2Q Sales EUR10.74B

30 Jun 2025, 15:09 UTC

Market Talk

Supreme Court Asks for Government's View on Bayer's Roundup Case -- Market Talk

5 Jun 2025, 08:29 UTC

Market Talk

Bayer Earnings Expectations Might Have Bottomed out -- Market Talk

30 May 2025, 13:47 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Consumer Health Sector Has Room for More Dealmaking -- Market Talk

Peer Comparison

Price change

Bayer AG Forecast

Price Target

By TipRanks

-4.17% downside

12 Months Forecast

Average 29.21 EUR  -4.17%

High 38.5 EUR

Low 23 EUR

Based on 10 Wall Street analysts offering 12 month price targets forBayer AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

3

Buy

7

Hold

0

Sell

Technical Score

By Trading Central

22.99 / 23.88Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

72 / 528 Finance

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.
help-icon Live chat